IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (243)	12/17/1996 10:30:00 AM
From: Don Cheng	of 1762

Hi Brad, What I heard from my broker regarding the recent action taken by SKB is as follows. As you know that the deal between SKB and IDPH worth about $60,000,000. The average price SKB bought IDPH is around $3/share, which give them about $60,000,000 worth of equity after they sold 400,000 shares early this month. Therefore he does not see any reasons for SKB to hold these additional 400,000 shares. The SKB was required to purchase these additional shares due to their contract with IDPH on CE9.1. Regardless IDEC-CE9.1 can be approved or not, their investment on IDPH has already paid back today. Unless SKB is interested in buying IDPH, there is no reason they would want to hold more than they invested in a small company like IDPH, which does not have a approved product yet. Don

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next